You have 9 free searches left this month | to do more
Showing 1 - 25 of
75 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma
Not yet recruiting
  • CNS Lymphoma
  • Zanubrutinib
  • (no location specified)
2021-11-02
Nov 2, 2021
Z
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
Recruiting
  • Immune Thrombocytopenia
  • Treatment
  • Zanubrutinib
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
2022-01-19
Jan 19, 2022
M
Zanubrutinib in Patients With IgG4-Related Disease
Not yet recruiting
  • IgG4 Related Disease
  • Zanubrutinib 80 MG
  • Palo Alto, California
    Stanford University
2022-01-12
Jan 12, 2022
Z
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Recruiting
  • Antiphospholipid Syndrome
  • +2 more
  • zanubrutinib
  • Tianjin, Tianjin, China
  • +1 more
2022-01-19
Jan 19, 2022
S
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL
Recruiting
  • Mantle Cell Lymphoma
  • Newly-diagnosed Mantle Cell Lymphoma
  • Zanubrutinib and Rituximab
  • +2 more
  • Guangzhou, Guangdong, China
  • +2 more
2021-05-26
May 26, 2021
H
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
Recruiting
  • Central Nervous System Lymphoma
  • Rituximab, Lenalidomide, Zanubrutinib
  • +2 more
  • Zhengzhou, Henan, China
    Henan cancer hospital
2021-06-16
Jun 16, 2021
P
A Study of Zanubrutinib in Patients With ITP
Recruiting
  • Immune Thrombocytopenia
  • Bruton Tyrosine Kinase
  • Zanubrutinib
  • Beijing, Beijing, China
    Peking University Insititute of Hematology, Peking University Pe
2022-03-06
Mar 6, 2022
I
Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL
Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
  • Zanubrutinib, bendamustine, rituximab
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
2022-03-18
Mar 18, 2022
J
Zanubrutinib + Venetoclax in CLL/SLL
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2022-03-16
Mar 16, 2022
H
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2022-01-22
Jan 22, 2022
F
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
Recruiting
  • Diffuse Large B-cell Lymphoma(DLBCL)
  • Zanubrutinib + R-CHOP
  • Shanghai, China
    Fudan University Shanghai Cancer Center
2022-02-10
Feb 10, 2022
B
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males - 2020
Completed
  • Healthy
  • Male
  • Daytona Beach, Florida
    Covance Clinical Research Unit
2021-08-30
Aug 30, 2021
B
A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Marginal Zone Lymphoma
Recruiting
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Zanubrutinib
  • +2 more
  • Westbury, New York
    Clinical Research Alliance, Inc.
2022-03-29
Mar 29, 2022
T
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • Zanubrutinib
  • +5 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
2021-04-12
Apr 12, 2021
B
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
Recruiting
  • Lupus Nephritis
  • Zanubrutinib
  • Placebo
  • Guangdong, Guangzhou, China
    Guangdong General Hospital
2021-03-17
Mar 17, 2021
B
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
Active, not recruiting
  • B-cell Malignancies
  • Zanubrutinib
  • +4 more
  • Concord, New South Wales, Australia
  • +6 more
2022-03-04
Mar 4, 2022
F
ZR-CHOP in DLBCL With Specific Gene Abnormality
Recruiting
  • Diffuse Large B Cell Lymphoma
  • zanubrutinib
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
2022-03-13
Mar 13, 2022
R
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
Recruiting
  • Primary Mediastinal Large B Cell Lymphoma
  • EBV-Positive DLBCL, Nos
  • Shanghai, Shanghai, China
    Ruijin Hospital
2021-03-29
Mar 29, 2021
P
Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL
Recruiting
  • Primary Vitreoretinal Lymphoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
2021-05-19
May 19, 2021
G
Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation
Recruiting
  • Richter Transformation
  • Tislelizumab
  • Zanubrutinib
  • Vienna, Austria
  • +11 more
2022-03-08
Mar 8, 2022
Z
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Rituximab, Lenalidomide, Zanubrutinib and RCHOP
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
2022-03-21
Mar 21, 2022
B
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma - 2020
Completed
Has Results
  • B-cell Lymphoma
  • Zanubrutinib
  • Beijing, Beijing, China
  • +3 more
2021-09-26
Sep 26, 2021
M
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Rituximab
  • Zanubrutinib
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-08
Feb 8, 2021
B
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
Recruiting
  • Mature B-cell Malignancies
  • Zanubrutinib
  • Nagoya, Aichi, Japan
  • +14 more
2021-02-18
Feb 18, 2021
G
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
Recruiting
  • Chronic Lymphoid Leukemia
  • Aachen, Germany
  • +20 more
2021-10-05
Oct 5, 2021